Gastroenteropancreatic Neuroendocrine Tumors Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Li

Gastroenteropancreatic Neuroendocrine Tumors emerging therapies such as TransCon hGH, HyTropin (GX-H9), Somatrogon, and others are expected to boost the Gastroenteropancreatic Neuroendocrine Tumors Market in the upcoming years.

DelveInsight has launched a new report on "Gastroenteropancreatic Neuroendocrine Tumors - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Gastroenteropancreatic Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our gastroenteropancreatic neuroendocrine tumors market report @ https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Gastroenteropancreatic Neuroendocrine Tumors Market Report:

Around 53% of patients with neuroendocrine tumors (NETs) are diagnosed with localized disease, while 20% present with locoregional involvement, and 27% have distant metastases at the time of diagnosis.
In April 2024, Novartis announced that the U.S. Food and Drug Administration (FDA) approved LUTATHERA for treating pediatric patients aged 12 and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including those originating in the foregut, midgut, and hindgut. This marks the first FDA-approved therapy specifically reviewed for pediatric GEP-NET patients.
In February 2024, RadioMedix and Orano Med revealed that the FDA granted Breakthrough Therapy Designation (BTD) to AlphaMedix (212Pb-DOTAMTATE) for adult patients with unresectable or metastatic, progressive somatostatin receptor-expressing GEP-NETs who have not previously received peptide receptor radionuclide therapy (PRRT).
The GEP-NET market is undergoing significant changes, driven by advancements in treatment options and the active involvement of leading pharmaceutical companies. Key players such as Camurus AB, ITM Isotope Technologies Munich, and others are spearheading research and development efforts to enhance therapies and shape market trends.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the second most prevalent type of cancer affecting the digestive system. Research indicates that the most common primary sites for NETs in the digestive tract are the small intestine (30.8%), colon (17.6%), pancreas (12.1%), and appendix (5.7%).
Key Gastroenteropancreatic Neuroendocrine Tumors companies such as Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicine, and others are evaluating new drugs for Gastroenteropancreatic Neuroendocrine Tumors to improve the treatment landscape.
Promising Gastroenteropancreatic Neuroendocrine Tumors pipeline therapies in various stages of development include Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC 001, and others.
Key benefits of the Gastroenteropancreatic Neuroendocrine Tumors market report:
Gastroenteropancreatic Neuroendocrine Tumors market report covers a descriptive overview and comprehensive insight of the Gastroenteropancreatic Neuroendocrine Tumors Epidemiology and Gastroenteropancreatic Neuroendocrine Tumors market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Gastroenteropancreatic Neuroendocrine Tumors market report provides insights on the current and emerging therapies.
Gastroenteropancreatic Neuroendocrine Tumors market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Gastroenteropancreatic Neuroendocrine Tumors market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Gastroenteropancreatic Neuroendocrine Tumors market.

Got queries? Click here to know more about the Gastroenteropancreatic Neuroendocrine Tumors Market Landscape https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Gastroenteropancreatic Neuroendocrine Tumors Overview

Neuroendocrine tumors (NETs) are a diverse group of neoplasms that develop from secretory cells within the diffuse neuroendocrine system. They are typically slow-growing and have the capacity to produce biogenic amines and peptide hormones. Gastroenteropancreatic NETs (GEP-NETs) encompass tumors originating in the gastrointestinal tract (GI-NETs) and pancreas (panNETs). Based on their morphology and proliferative activity, they are classified into well-differentiated tumors (low-, intermediate-, or high-grade) and poorly differentiated carcinomas (NECs).

The diagnosis of GEP-NETs relies on clinical evaluation, pathological findings, and both conventional and functional imaging techniques. Conventional imaging is crucial for determining the tumor's location and extent, with cross-sectional imaging-such as computed tomography (CT) and magnetic resonance imaging (MRI)-being particularly useful. For pancreatic NETs (pNETs), imaging focuses on the abdomen, while midgut carcinoids require assessment of both the abdomen and pelvis.

The Gastroenteropancreatic NET report offers a comprehensive overview of GEP-NET pathophysiology, diagnostic methods, and treatment protocols. It also presents a real-world perspective on a patient's journey, detailing the progression from initial symptoms and diagnosis to the complete treatment process.

Gastroenteropancreatic Neuroendocrine Tumors Treatment Market

Surgery remains the only curative option for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and is typically the first-line treatment for localized cases. However, despite advancements in diagnostic techniques, GEP-NETs often go undetected for 5-7 years after symptom onset due to their nonspecific clinical presentation.

For metastatic GEP-NETs, somatostatin analogs serve as the primary treatment, with two FDA-approved options: SANDOSTATIN (octreotide acetate) and SOMATULINE DEPOT (lanreotide). When patients experience disease progression on frontline therapy, there is currently limited consensus on the optimal next-line treatment. Traditionally, the mTOR inhibitor everolimus or sunitinib (SUTENT) has been considered the standard second-line option. However, with the recent approval of peptide receptor radionuclide therapy (PRRT), the choice of second-line treatment remains a topic of ongoing debate.

To know more about how the gastroenteropancreatic neuroendocrine tumors treatment market is rising, click: https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Gastroenteropancreatic Neuroendocrine Tumors Market Outlook

Leading companies such as ITM Isotope Technologies Munich, Camurus AB, and others are actively advancing their key drug candidates through various stages of clinical development, aiming to explore their potential for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The range of systemic treatments for advanced GEP-NETs continues to grow. Somatostatin analogs (SSAs) remain a cornerstone of therapy, particularly for patients with hormonally active tumors and midgut carcinoids.

A widening array of systemic treatment options is now available for advanced NETs. While targeted therapies that inhibit angiogenesis and the mTOR pathway have been introduced, the role of cytotoxic chemotherapy remains a subject of debate, leading to significant variations in treatment practices across different countries. Emerging insights into the genetic characteristics of GEP-NETs are expected to drive the development of predictive biomarkers, enabling more personalized and strategic treatment sequencing.

Among global markets, the United States holds the largest market share for GEP-NETs, surpassing the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Gastroenteropancreatic NET Marketed Drugs:
LUTATHERA: Novartis
SOMATULINE DEPOT: Ipsen Biopharmaceuticals

Gastroenteropancreatic NET Emerging Drugs:
CAM2029: Camurus AB
ITM-11: ITM Isotope Technologies Munich

To get detailed insights on the gastroenteropancreatic neuroendocrine tumors treatment algorithm and therapies, visit: https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Gastroenteropancreatic Neuroendocrine Tumors Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Gastroenteropancreatic Neuroendocrine Tumors Companies: Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicine, and others
Key Gastroenteropancreatic Neuroendocrine Tumors Therapies: LUTATHERA, SOMATULINE DEPOT, CAM2029, ITM-11, and others
Gastroenteropancreatic Neuroendocrine Tumors Therapeutic Assessment: Gastroenteropancreatic Neuroendocrine Tumors current marketed and Gastroenteropancreatic Neuroendocrine Tumors emerging therapies
Gastroenteropancreatic Neuroendocrine Tumors Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumors market drivers and Gastroenteropancreatic Neuroendocrine Tumors market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs, KOL's views, Analyst's views, Gastroenteropancreatic Neuroendocrine Tumors Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Gastroenteropancreatic Neuroendocrine Tumors Patient Share (%) Overview at a Glance
5. Gastroenteropancreatic Neuroendocrine Tumors Market Overview at a Glance
6. Gastroenteropancreatic Neuroendocrine Tumors Disease Background and Overview
7. Gastroenteropancreatic Neuroendocrine Tumors Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastroenteropancreatic Neuroendocrine Tumors
9. Gastroenteropancreatic Neuroendocrine Tumors Current Treatment and Medical Practices
10. Unmet Needs
11. Gastroenteropancreatic Neuroendocrine Tumors Emerging Therapies
12. Gastroenteropancreatic Neuroendocrine Tumors Market Outlook
13. Country-Wise Gastroenteropancreatic Neuroendocrine Tumors Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Gastroenteropancreatic Neuroendocrine Tumors Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Gastroenteropancreatic Neuroendocrine Tumors Market Outlook 2034 https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Gastroenteropancreatic Neuroendocrine Tumors Pipeline Insights, DelveInsight

"Gastroenteropancreatic Neuroendocrine Tumors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Gastroenteropancreatic Neuroendocrine Tumors market. A detailed picture of the Gastroenteropancreatic Neuroendocrine Tumors pipeline landscape is provided, which includes the disease overview and Gastroenteropancreatic Neuroendocrine Tumors treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.